Company Description
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH.
The company was incorporated in 2013 and is based in Pudong, China.
| Country | China |
| Founded | 2013 |
| IPO Date | Sep 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,784 |
| CEO | Ying Du |
Contact Details
Address: Building B, 899 Halei Road Pudong, 201203 China | |
| Phone | 86 21 6163 2588 |
| Website | zailaboratory.com |
Stock Details
| Ticker Symbol | ZLAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001704292 |
| CUSIP Number | 98887Q104 |
| ISIN Number | US98887Q1040 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ying Du Ph.D. | Founder, Chairperson and Chief Executive Officer |
| Joshua L. Smiley | President and Chief Operating Officer |
| Dr. Rafael G. Amado M.D. | President and Head of Global Research and Development |
| Dr. Yajing Chen Ph.D. | Chief Financial Officer |
| Frazor Titus Edmondson III, J.D. | Chief Legal Officer and Corporate Secretary |
| Christine Chiou | Senior Vice President and Head of Investor Relations |
| Dr. James Yan DABT, M.D., Ph.D. | Chief Operating Officer of Research & Development |
| Tong Zhu | Chief Commercial Officer of Greater China |
| Dr. Shan He Ph.D. | Senior Vice President and Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 6, 2026 | SCHEDULE 13G | Filing |
| Apr 6, 2026 | 144 | Filing |
| Apr 6, 2026 | 144 | Filing |
| Apr 6, 2026 | 144 | Filing |
| Apr 6, 2026 | 144 | Filing |
| Apr 6, 2026 | 144 | Filing |